Additionally, several factors influence the effectiveness of CAR T-cell therapy, including a pro-inflammatory state, the tumor microenvironment, PPM1D mutations, single nucleotide polymorphisms in the cluster of differentiation 19 (CD19) antigens, and circulating monocytes. This evidence concerns the gene PPM1D and neoplasm.